自1979年被发现以来，p53蛋白已成为了研究最为广泛和深入的肿瘤抑制因子之一。作为转录因子，p53调控众多下游信号通路，诱导细胞周期停滞、细胞凋亡和衰老是其最“经典”的功能，也被认为是其清除受损细胞、防止癌细胞发生的主要手段。学术经纬相关阅读：人类天生拥有的肿瘤克星！《细胞》子刊：45年来，我们对p53了解有多 ...

The role of EGFR in KRASG12D-driven tumorigenesis was studied using mouse CRC organoids with KRAS-APC-TP53 mutations and ...

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are ...

NTS071 is an oral small molecule allosteric reactivator targeting p53 Y220C with a novel scaffold. It selectively binds to ...

A hidden clue may explain why some mutated cells become cancerous and others don’t: how fast they divide. A new study from ...

Australian researchers have discovered that a single mutation in the DNA sequence for a methylation enzyme dysregulates key ...

Sustained reactivation of mutant p53 drives durable anti-tumor activity across models, including KRAS co-mutant tumorsFMC-220 selectively stabilizes p53 Y220C at lower doses, overcoming key ...

This mutation destabilizes the p53 protein—often referred to as the “guardian of the genome”—and impairs its tumor-suppressive functions, contributing significantly to cancer progression.

In the study, patients with advanced solid tumors must be HLA-A*02:01 positive and harbor a p53 R175H mutation.

CAMBRIDGE, MA and ROCKVILLE, MD, USA I April 28, 2025 I Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology with ...